Results 21 to 30 of about 106,112 (301)

Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]

, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro, González-Fernández, María, Herrero, Alicia, Jiménez-Nácher, Inmaculada, Moreno, Francisco, Villamañán, Elena   +5 more
core   +3 more sources

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis

Качественная клиническая практика, 2020
Rationale. Rheumatoid arthritis (RA) and systemic juvenile arthritis (sJA) are the most frequent rheumatic diseases in adults and adolescents, consequently. Biologics disease modifying antirheumatic drugs (bDMARDs) are eff ective in treatment of RA and s
A. S. Kolbin, A. A. Kurylev, S. A. Mishinova, Yu. E. Balykina, M. A. Proskurin   +4 more
doaj   +1 more source

Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation

Frontiers in Genetics, 2021
COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19.
Arya Zarinsefat, George Hartoularos, Dmitry Rychkov, Priyanka Rashmi, Sindhu Chandran, Flavio Vincenti, Chun J. Yee, Minnie M. Sarwal   +7 more
doaj   +1 more source

Eosinophilic fasciitis (Shulman's disease): review and comparative evaluation of seven patients. [PDF]

, 2019
OBJECTIVES: Eosinophilic fasciitis (EF) was described in 1974 by Shulman as a rare fibrosing connective tissue disease of unknown etiology. An undetermined trigger is thought to lead to the degranulation of eosinophils that interact with fibroblasts and
Cimbron, M, Farinha, F, Mendonça, T, Urzal, J   +3 more
core   +1 more source

Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up

EClinicalMedicine, 2020
Background: Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage.
Nicola De Rossi, Cristina Scarpazza, Chiara Filippini, Cinzia Cordioli, Sarah Rasia, Chiara Rosa Mancinelli, Damiano Rizzoni, Giuseppe Romanelli, Stefania Cossi, Nereo Vettoretto, Sergio Bove, Silvano Manfredini, Eva Andrea Beindorf, Carlo Mosca, Vittorio Scipione, Gigliola Flamminio, Elena Albini Albini, Paola Giansiracusa, Ruggero Capra   +18 more
doaj   +1 more source

Avaliação à medida no Segundo HAREM [PDF]

, 2008
Objectives This study compared the efficacy and safety of subcutaneous (SC) versus intravenous (IV) formulations of tocilizumab in patients with rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (DMARD).
Bao, Min, Burmester, Gerd R., Cantagrel, Alain, Feldman, Daniel, Hall, Stephen, Leszczynski, Piotr, Lu, Peng, Ludivico, Charles, Mysler, Eduardo F., Rangaraj, Madura J., Roane, Georgia, Rowell, Lucy, Rubbert-Roth, Andrea   +12 more
core   +2 more sources

Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab

Open Heart, 2023
Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with
Ola Kleveland, Rune Wiseth, Jan Kristian Damås, Pål Aukrust, Lars Gullestad, Bente Halvorsen, Einar Hopp, Kaspar Broch, T Ueland, Anne Kristine Anstensrud, Sindre Woxholt, Bjørn Bendz, Brage H Amundsen, Nils-Einar Kløw, Ingebjørg Seljeflot, Geir Øystein Andersen, Ingvild Maria Tøllefsen, Liv Ryan, Tuva B Dahl, Camilla Huse   +19 more
doaj   +1 more source

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Pediatric Rheumatology Online Journal, 2018
Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and
Ju-Yang Jung, Moon-Young Kim, Chang-Hee Suh, Hyoun-Ah Kim   +3 more
doaj   +1 more source

How and why systemic inflammation worsens quality of life in patients with advanced cancer [PDF]

, 2017
Introduction: The presence of an innate host systemic inflammatory response has been reported to be a negative prognostic factor in a wide group of solid tumour types in both the operable and advanced setting, both local and distant.
Dolan, Ross D., Horgan, Paul G., McMillan, Donald C., McSorley, Stephen T., Roxburgh, Campbell S.D.   +4 more
core   +1 more source